Anna Rutkowska

This file contain information on the Cell lines and organoids used in this study

This file contains details of the BE sgRNA library

Supplementary Figure 1. Generating base editor-expressing MSI cell lines for screening. Supplementary Figure 2. Quality control for base-editor screens in MSI cell lines. Supplementary Figure 3. Discovery and characterization of novel inhibitors of WRN helicase. Supplementary Figure 4. Correlation of WRN inhibitor sensitivity with genetic and molecular markers in MSI models. Supplementary Figure 5. Comparative analysis of DNA damage in MSI and MSS cells treated with WRN inhibitors and genetic inactivation. Supplementary Figure 6: Effects of GSK_WRN4 on MSI and MSS colorectal cancer xenografts.

This table lists the results from Base editing screen

Adverse events in the different subgroups of the PRIMA study

Patient characteristics for PRIMA/NOVA/QUADRA – statins concomitant

QUADRA patient characteristics and baseline demographics

Retrospective analysis of PRIMA clinical trial in the HRd and HRp groups – stratified by patient characteristics (age and weight) and statin treatment (type of statin and its dose level)

Results of analysis from the PRIMA clinical trials

PRIMA Patient Characteristics and Baseline Demographics